Overview

Lenalidomide and R-CHOP in B-cell Lymphoma

Status:
Completed

Trial end date:
2015-11-23

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Lymphoma Study Association

Treatments:

Lenalidomide
Thalidomide